



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/017,905	12/14/2001	Paul M. Ridker	B0801/7238 (ERG/KA)	7653
7590	07/09/2008		EXAMINER	
Edward R. Gates Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza 600 Atlantic Avenue Boston, MA 02210			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			07/09/2008	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/017,905	RIDKER ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	G. R. Ewoldt, Ph.D.	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 09 May 2008.

2a) This action is **FINAL**.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1,6,11,16,21,52,55,57,62-68 and 71-76 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1,6,11,16,21,52,55,57,62-68 and 71-76 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>5/9/08</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____

Art Unit: 1644

**DETAILED ACTION**

1. Applicant's remarks and IDS filed 5/09/08, have been entered.
2. Claims 1, 6, 11, 16, 21, 52, 55, 57, 62-68, and 71-76 are being acted upon.
3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1, 6, 11, 16, 21, 52, 55, 57, 62-68, and 71-76 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Rodriguez-Moran et al. (1999) in view of Rohlfing, C.L., et al. (2000) and Chapin. B.L., et al. (1999).

As set forth previously, Rodriguez-Moran et al. teaches that elevated serum CRP levels have been found in type II diabetics and in diabetics with foot ulcers (see particularly page 211, column 2). The reference also teaches that elevated serum CRP levels are also found in noncontrolled type II diabetic patients. (see particularly Table 2).

Rodriguez-Moran et al. does not teach the characterizing a risk profile for developing diabetes in an apparently healthy individual nor evaluating the likelihood that an individual will benefit from treatment.

Rohlfing et al. teaches the use of a screening assay for undiagnosed diabetes and/or complications thereof (see particularly page 187 and CONCLUSIONS).

Chapin et al. teaches that even apparently healthy individuals who undergo regular physical examinations can suffer from undiagnosed diabetes and/or complications thereof (see particularly Table 2).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made measure serum CRP levels for uses such as characterizing a risk profile for developing diabetes in an apparently healthy individual or evaluating the likelihood that an individual will benefit from treatment given CRP's known association with type II diabetes, as taught by Rodriguez-Moran et al., given that it is well known to measure a known marker for the presence of, or predisposition to, diabetes, as taught by Rohlfing et al., even in apparently healthy individuals because even apparently healthy individuals can suffer from undiagnosed diabetes and/or complications thereof, as taught by Chapin et al. Note that the choice of any particular serum CRP concentration as an indicator of disease comprises no more than routine optimization of the claimed

Art Unit: 1644

method and falls well within the purview of the ordinarily skilled artisan.

Applicant's arguments, filed 5/09/08, have been fully considered but are not found persuasive. Applicant again makes a curious argument that the teachings of Rodriguez-Moran et al. cannot be used to render obvious the predictive value of CRP levels for future diabetes. Applicant is advised that if this argument were to be found persuasive then a rejection for lack of enablement would be required given the fact that the example in the specification does not show said predictive value either.

Applicant cites the Example in support.

A careful review of the Example reveals that its methodology is so flawed as to render the results meaningless. Table 1 clearly shows that the majority of the "Cases" in the study did not meet Applicant's definition of "apparently healthy". Note that 58.5% of the individuals reported a "History of Hypertension". Another 43.6 of the "Cases" reported a "History of Hyperlipidemia". "Apparently healthy" is defined at page 9 as "free of symptoms of disease", which most of the subjects in this study clearly were not.

Applicant argues that Chapin et al. describes asymptomatic individuals whereas the claims are drawn to a method involving apparently healthy individuals.

A review of the specification reveals that apparently healthy individuals is defined as including individuals absent symptoms and previous clinical evidence of disease. Before the tests of Chapin et al. the subjects presented no clinical evidence of disease and, thus, they were included in the study because they were "apparently healthy". Indeed, individuals with known diabetes were excluded from the tests.

The testing of apparently healthy individuals for diseases and conditions which they do not know they have is the hallmark of preventive medicine. Whether it be taking a blood pressure to check for possible hypertension, checking PSA levels to check for the possibility of prostate cancer (including future prostate cancer), or checking genetic polymorphisms as predictor of future cancers, the screening of apparently healthy individuals employing markers found in blood or other tissue for a myriad of future problems is routine and obvious in the medical art.

Art Unit: 1644

5. Claims 1, 6, 11, 16, 21, 52, 55, 57, 62-68, and 71-76 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Schalkwijk et al. (1999) in view of Rohlfing, C.L., et al. (2000) and Chapin. B.L., et al. (1999).

As set forth previously, Schalkwijk et al. teaches that elevated serum CRP levels have been found in type I diabetics and in diabetics with foot ulcers (see particularly page 211, **Results** and Table 2).

Schalkwijk et al. does not teach the characterizing a risk profile for developing diabetes in an apparently healthy individual nor evaluating the likelihood that an individual will benefit from treatment.

Rohlfing et al. and Chapin et al. have been discussed above.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made measure serum CRP levels for uses such as characterizing a risk profile for developing diabetes in an apparently healthy individual or evaluating the likelihood that an individual will benefit from treatment given CRP's known association with type I diabetes, as taught by Schalkwijk et al., given that it is well known to measure a known marker for the presence of, or predisposition to, diabetes, as taught by Rohlfing et al., even in apparently healthy individuals because even apparently healthy individuals can suffer from undiagnosed diabetes and/or complications thereof, as taught by Chapin et al. Note that the choice of any particular serum CRP concentration as an indicator of disease comprises no more than routine optimization of the claimed method and falls well within the purview of the ordinarily skilled artisan.

Applicant presents arguments essentially the same as presented regarding the rejection in view of Rodriguez-Moran et al.

See the Examiner's response in Section 5.

6. No claim is allowed.

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 1644

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara, Ph.D. can be reached on (571) 272-0878.

9. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

/G.R. Ewoldt/  
G.R. Ewoldt, Ph.D.  
Primary Examiner  
Technology Center 1600